Senores Pharma: No Deviation in IPO Fund Utilization for Q1 FY27
Senores Pharmaceuticals confirms no deviation in IPO fund utilization for the quarter ended June 30, 2026. The company raised ₹500 Crores via IPO in December 2024. While most allocations are utilized as planned, minor delays exist in capital expenditure funding for a manufacturing facility, with shareholder approval sought for adjustments.
This announcement is a routine regulatory filing regarding the utilization of IPO funds. As there are no significant deviations or variations reported, the market impact is expected to be low.
The company reported no deviations in IPO fund utilization, which is a neutral regulatory filing. While there are minor delays noted in specific project fund deployment, no negative financial impact is indicated.
Senores Pharmaceuticals Limited has submitted its statement of deviations or variations in the utilization of funds raised through its Initial Public Offer (IPO) for the quarter ended June 30, 2026. The company confirms that there have been no deviations or variations in the utilization of IPO proceeds as per the objectives stated in the Prospectus dated December 24, 2024.
The statement was reviewed by the Audit Committee and taken on record by the Board of Directors on July 27, 2026. The company raised ₹500 Crores through its IPO on December 26, 2024.
Details of fund utilization show that out of the original allocation of ₹107.00 Crores for investment in its subsidiary, Havix, to fund capital expenditure for a manufacturing facility, ₹6.98 Crores were utilized during the quarter. The company notes an ongoing delay in the deployment of funds under this object and has sought shareholder approval for variation in objects and an extension of time.
For the repayment/prepayment of certain borrowings, ₹73.10 Crores were utilized against an original allocation of ₹73.48 Crores. An unutilized amount of ₹0.38 Crore was transferred to General Corporate Purposes (GCP) as resolved in a Board Meeting on July 23, 2025.
Similarly, for investment in subsidiary Havix for repayment of borrowings, ₹20.20 Crores were utilized against an allocation of ₹20.22 Crores, with ₹0.02 Crore transferred to GCP. Funding working capital requirements of the company utilized the entire allocated ₹43.26 Crores. Investment in subsidiaries SPI and Ratnatris for their working capital requirements also utilized the full allocated ₹59.48 Crores.
Funding inorganic growth and other strategic initiatives saw utilization of ₹161.63 Crores against a modified allocation of ₹161.91 Crores, with ₹7.54 Crores transferred from other objectives.
For offer expenses, ₹34.80 Crores were utilized against a modified allocation of ₹35.04 Crores. Unutilized amounts from this objective were transferred to other objectives as per Board resolutions on March 28, 2026, and May 14, 2026.
The total funds raised were ₹500.00 Crores, with a total utilization reported as ₹399.46 Crores.
What to do with a filing like this
Senores Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Senores Pharmaceuticals Limited. Read the original for the full detail.